153 related articles for article (PubMed ID: 26600382)
1. Attitudes toward Placebo-Controlled Clinical Trials of Patients with Schizophrenia in Japan.
Sugawara N; Ishioka M; Tsuchimine S; Tsuruga K; Sato Y; Furukori H; Kudo S; Tomita T; Nakagami T; Yasui-Furukori N
PLoS One; 2015; 10(11):e0143356. PubMed ID: 26600382
[TBL] [Abstract][Full Text] [Related]
2. Attitudes toward placebo-controlled clinical trials among depressed patients in Japan.
Sugawara N; Ishioka M; Tsuchimine S; Tsuruga K; Sato Y; Tarakita N; Furukori H; Kudo S; Tomita T; Nakagami T; Yasui-Furukori N
J Affect Disord; 2018 Jan; 225():313-316. PubMed ID: 28843082
[TBL] [Abstract][Full Text] [Related]
3. Attitudes of patients with schizophrenia toward placebo-controlled clinical trials.
Hummer M; Holzmeister R; Kemmler G; Eder U; Hofer A; Kurzthaler I; Oehl M; Weiss E; Fleischhacker WW
J Clin Psychiatry; 2003 Mar; 64(3):277-81. PubMed ID: 12716268
[TBL] [Abstract][Full Text] [Related]
4. Attitudes toward menstruation in females with schizophrenia or schizoaffective disorders in Taiwan.
Liang HY; Lee LW; Kelsen BA; Hsu SC; Liu CY; Chen CY
Climacteric; 2013 Dec; 16(6):682-8. PubMed ID: 23205628
[TBL] [Abstract][Full Text] [Related]
5. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
Woods SW; Gueorguieva RV; Baker CB; Makuch RW
Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
[TBL] [Abstract][Full Text] [Related]
6. Public attitudes regarding willingness to participate in medical research studies.
Trauth JM; Musa D; Siminoff L; Jewell IK; Ricci E
J Health Soc Policy; 2000; 12(2):23-43. PubMed ID: 11184441
[TBL] [Abstract][Full Text] [Related]
7. [Tunisian mothers' beliefs about their child's first psychotic episode].
Bourgou S; Halayem S; Bouden A; Halayem MB
Encephale; 2012 Dec; 38(6):473-9. PubMed ID: 23200613
[TBL] [Abstract][Full Text] [Related]
8. Raloxifene Plus Antipsychotics Versus Placebo Plus Antipsychotics in Severely Ill Decompensated Postmenopausal Women With Schizophrenia or Schizoaffective Disorder: A Randomized Controlled Trial.
Weiser M; Levi L; Burshtein S; Hagin M; Matei VP; Podea D; Micluția I; Tiugan A; Păcală B; Grecu IG; Noy A; Zamora D; Davis JM
J Clin Psychiatry; 2017 Jul; 78(7):e758-e765. PubMed ID: 28541645
[TBL] [Abstract][Full Text] [Related]
9. The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.
Janicak PG; Glick ID; Marder SR; Crandall DT; McQuade RD; Marcus RN; Eudicone JM; Assunção-Talbott S
J Clin Psychiatry; 2009 Jan; 70(1):25-35. PubMed ID: 19192472
[TBL] [Abstract][Full Text] [Related]
10. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals.
Day JC; Bentall RP; Roberts C; Randall F; Rogers A; Cattell D; Healy D; Rae P; Power C
Arch Gen Psychiatry; 2005 Jul; 62(7):717-24. PubMed ID: 15997012
[TBL] [Abstract][Full Text] [Related]
11. Veteran subjects willingness to participate in schizophrenia clinical trials.
Hoblyn JC; Rosenheck RA; Leatherman S; Weil L; Lew R;
Psychiatr Q; 2013 Jun; 84(2):209-18. PubMed ID: 23143523
[TBL] [Abstract][Full Text] [Related]
12. Hypertensive patients' willingness to participate in placebo-controlled trials: implications for recruitment efficiency.
Halpern SD; Karlawish JH; Casarett D; Berlin JA; Townsend RR; Asch DA
Am Heart J; 2003 Dec; 146(6):985-92. PubMed ID: 14660989
[TBL] [Abstract][Full Text] [Related]
13. [Relationship between insight and self-reported quality of life among shizophrenic patients].
Aghababian V; Auquier P; Baumstarck-Barrau K; Lançon C
Encephale; 2011 Jun; 37(3):162-71. PubMed ID: 21703431
[TBL] [Abstract][Full Text] [Related]
14. Placebo Response and Practice Effects in Schizophrenia Cognition Trials.
Keefe RSE; Davis VG; Harvey PD; Atkins AS; Haig GM; Hagino O; Marder S; Hilt DC; Umbricht D
JAMA Psychiatry; 2017 Aug; 74(8):807-814. PubMed ID: 28636694
[TBL] [Abstract][Full Text] [Related]
15. Patients' attitudes to the use of placebos: results from a New Zealand survey.
Chen GF; Johnson MH
N Z Med J; 2009 Jun; 122(1296):35-46. PubMed ID: 19652679
[TBL] [Abstract][Full Text] [Related]
16. [Assessing beliefs and attitudes of relatives of patients with schizophrenia: a study in a Tunisian sample].
Bouhlel S; Ben Haouala S; Klibi A; Ghaouar M; Chennoufi L; Melki W; El-Hechmi Z
Encephale; 2013 Jun; 39(3):165-73. PubMed ID: 23095602
[TBL] [Abstract][Full Text] [Related]
17. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
Swainston Harrison T; Perry CM
Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials.
Kane JM; Barnes TR; Correll CU; Sachs G; Buckley P; Eudicone J; McQuade R; Tran QV; Pikalov A; Assunção-Talbott S
J Psychopharmacol; 2010 Jul; 24(7):1019-29. PubMed ID: 20008446
[TBL] [Abstract][Full Text] [Related]
19. Augmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: a randomized controlled trial.
Zisook S; Kasckow JW; Lanouette NM; Golshan S; Fellows I; Vahia I; Mohamed S; Rao S
J Clin Psychiatry; 2010 Jul; 71(7):915-22. PubMed ID: 20361918
[TBL] [Abstract][Full Text] [Related]
20. Vitamin B6 as add-on treatment in chronic schizophrenic and schizoaffective patients: a double-blind, placebo-controlled study.
Lerner V; Miodownik C; Kaptsan A; Cohen H; Loewenthal U; Kotler M
J Clin Psychiatry; 2002 Jan; 63(1):54-8. PubMed ID: 11838627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
